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Mineralocorticoid Modulation of Cardiac Ryanodine
Receptor Activity Is Associated With Downregulation of
FK506-Binding Proteins
Ana María Gómez, PhD; Angélica Rueda, PhD; Yannis Sainte-Marie, PhD; Laetitia Pereira, PhD;
Spyros Zissimopoulos, PhD; Xinsheng Zhu, PhD; Roxane Schaub, MD; Emeline Perrier, PhD;
Romain Perrier, PhD; Céline Latouche, MS; Sylvain Richard, PhD; Marie-Christine Picot, MD, PhD;
Frederic Jaisser, MD, PhD; F. Anthony Lai, PhD; Héctor H. Valdivia, MD, PhD;
Jean-Pierre Benitah, PhD
Background—The mineralocorticoid pathway is involved in cardiac arrhythmias associated with heart failure through
mechanisms that are incompletely understood. Defective regulation of the cardiac ryanodine receptor (RyR) is an
important cause of the initiation of arrhythmias. Here, we examined whether the aldosterone pathway might modulate
RyR function.
Methods and Results—Using the whole-cell patch clamp method, we observed an increase in the occurrence of delayed
afterdepolarizations during action potential recordings in isolated adult rat ventricular myocytes exposed for 48 hours
to aldosterone 100 nmol/L, in freshly isolated myocytes from transgenic mice with human mineralocorticoid receptor
expression in the heart, and in wild-type littermates treated with aldosterone. Sarcoplasmic reticulum Ca2 load and RyR
expression were not altered; however, RyR activity, visualized in situ by confocal microscopy, was increased in all cells,
as evidenced by an increased occurrence and redistribution to long-lasting and broader populations of spontaneous Ca2
sparks. These changes were associated with downregulation of FK506-binding proteins (FKBP12 and 12.6), regulatory
proteins of the RyR macromolecular complex.
Conclusions—We suggest that in addition to modulation of Ca2 influx, overstimulation of the cardiac mineralocorticoid
pathway in the heart might be a major upstream factor for aberrant Ca2 release during diastole, which contributes to
cardiac arrhythmia in heart failure. (Circulation. 2009;119:2179-2187.)
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During the past decade, research has focused on theactions of aldosterone in target organs beyond the
kidney, expanding the role of the aldosterone pathway in
cardiovascular pathogenesis.1 Indeed, mineralocorticoid re-
ceptors (MRs), which mainly underlie aldosterone action,
have been detected in a range of nonrenal tissues, including
the brain, blood vessels, and heart,2 which suggests a broader
pattern of biological activity for aldosterone than previously
anticipated. The pivotal role of aldosterone, causing sodium
retention with expansion of the extracellular volume that
results in deterioration of hemodynamic responsiveness and a
fall in cardiac output, has long been recognized in heart
failure (HF).3,4 In addition, accumulating experimental and
clinical evidence suggests that aldosterone has direct adverse
cardiac effects independent of its effects on blood pressure,
especially an increased risk of arrhythmic death.3,4 Interest-
ingly, major clinical trials involving MR antagonists have
shown significant benefits on risk of cardiovascular events, in
particular sudden death in HF.5,6 A pertinent question, there-
fore, is how activation of cardiac MR participates in life-
threatening arrhythmias.
Clinical Perspective p 2187
Most fatal arrhythmias in experimental HF are initiated by
nonreentrant mechanisms that arise from abnormal ventricular
automaticity or triggered activity.7,8 The latter consists of either
early afterdepolarizations (EADs) that occur in the plateau phase
of the action potential (AP) or delayed afterdepolarizations
(DADs) that occur at repolarized membrane potentials.9 EADs
typically occur in the setting of prolonged repolarization due to
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alterations in ionic currents and to reactivation of the Ca2
current (ICa). DADs are caused by membrane depolarization
initiated by spontaneous Ca2 release from the sarcoplasmic
reticulum (SR) through the ryanodine receptor (RyR). We have
accumulated evidence, both ex vivo and in vivo, that modulation
of Ca2 influx is a central factor in the cardiac action of the
aldosterone pathway10–14 and might be involved in EAD-related
fatal ventricular tachyarrhythmia.14 Moreover, enhanced diastol-
ic leak of Ca2 via RyRs generates DADs and is a fundamental
mechanism underlying several genetic or acquired arrhyth-
mias.15,16 Therefore, we tested whether activation of the aldo-
sterone pathway modulates diastolic RyR activity in heart.
Methods
All experiments were performed according to European Union Council
Directives (86/609/EEC) for the care of laboratory animals. A detailed
Methods section can be found in the online-only Data Supplement.
Cell Isolation and Incubation
Isolated ventricular myocytes from adult male Wistar rats (250 to 350 g;
Elevage Janvier, Le Genest Saint Isle, France) were incubated for 48
hours, with or without D-aldosterone 100 nmol/L (Sigma, Saint Quentin
Fallaviere, France). In some experiments, RU28318 10 mol/L was
added to aldosterone.10,11
Human MR Transgenic Mice and In Vivo
Aldosterone Exposure
Cardiac-specific expression of human MR (hMR) was obtained by
crossing a tetO-hMR mouse strain with an -MHC-tTA transactivator
mouse strain.14 Littermate wild-type, gender-matched mice (WT) were
used as controls. In some of these, after pentobarbital sodium anesthesia
(30 mg/kg) was administered, osmotic minipumps (model 2 ML4, Alza
Corp, Mountain View, Calif) were implanted subcutaneously for con-
stant delivery of D-aldosterone 50 g/d (dissolved in 0.9% saline) over
3 weeks. Chronic aldosterone infusion significantly increased the
plasma aldosterone concentration above control levels (from 27877
[n7] to 1374150 [n7] pg/mL, P0.05). Mice were devoid of
cardiac hypertrophy either on the whole-organ level (heart weight–to–
body weight ratio 5.90.4 [n15], 5.90.3 [n11], and 5.30.4 mg/g
[n6] in WT, aldosterone-treated, and hMR mice, respectively;
P0.05) or at the cellular level (membrane capacitance 201.86.1
[n30], 199.612.7 [n21], and 199.011.0 pF [n26] for isolated
ventricular myocytes from WT, aldosterone-treated, and hMR mice,
respectively; P0.05).
AP Recording
The whole-cell patch-clamp method was used in the current-clamp
configuration to record APs with solutions and protocol as described
previously.11
Spontaneous Local SR Ca2 Release: Ca2 Sparks
Fluo-3AM–loaded cells were imaged in Tyrode solution (in mmol/L:
NaCl 130, NaH2PO4 0.4, NaHCO3 5.8, CaCl2 1, MgCl2 0.5, KCl 5.4,
glucose 22, HEPES 25, insulin 0.01, pH 7.4) with a confocal micro-
scope in line-scan mode.11
Cell Lysate and SR-Enriched Membrane Fraction
(SR Fraction)
Cell lysates were prepared with homogenization buffer (in mmol/L:
sucrose 300, NaF 20, HEPES 20, aprotinin 5.2 104, benzamidine 0.5,
leupeptin, 0.012, PMSF 0.1, pH 7.2) with a Potter-Elvehjem homoge-
nizer and spun at 2000 g for 10 minutes. SR fractions were isolated by
ultracentrifugation at 40 000 g for 30 minutes at 4°C.17 Protein concen-
tration by the Bradford method and binding of [3H]ryanodine to SR
fractions were assessed.17
Single-Channel Recordings
Analysis of RyR single-channel activity was done by fusing SR vesicles
into planar lipid bilayers with Cs as a charge carrier.17 Only bilayers
that contained a single channel were used. Channel activity was always
tested for sensitivity to EGTA, which was added in the cis chamber at
the end of each experiment.
Reverse-Transcription Polymerase Chain
Reaction Analysis
Total RNA was extracted with Trizol (Invitrogen, Cergy Pontoise,
France). First-strand cDNA was synthesized after DNaseI treatment
(DNAfree, Ambion, Courtaboeuf, France) with 1 g of total RNA,
random hexamers (Amersham, Biosciences Europe GMBH, Orsay,
France), and Superscript II reverse transcriptase (Invitrogen). Transcript
levels were analyzed in triplicate by real-time polymerase chain reaction
with an iCycler iQ apparatus (Bio-Rad, Marnes la Coquette, France)
with a qPCR Core Kit for SYBR Green I (Eurogentec, Brussels,
Belgium) that contained 500 nmol/L of specific primers (Data Supple-
ment, Table I) and 3 L of diluted template cDNA. Relative expression
of FK506-binding proteins (FKBPs) and RyR was normalized by the
geometric average of relative quantities for reference genes. Serial
dilutions of pooled cDNA were used in each experiment to assess the
efficiency of the polymerase chain reaction.
Immunoblots
Immunoblots were prepared from cell lysates with anti-FKBP12/
12.6 (1:1000, Santa-Cruz Biotechnology Inc, Santa Cruz, Calif), anti-RyR
(1:3000, Affinity BioReagents, Golden, Colo), and anti-actin (1:20 000,
Sigma) antibodies. FKBP12/12.6-RyR interaction was assessed on SR
fractions with anti-FKBP12/12.6 (1:200) and anti-RyR (1:1000) antibodies
from Affinity BioReagents. Immunoblots of RyR phosphorylation were
performed with anti–RyR-PS2809 (1:5000) antibody from Badrilla (Leeds,
West Yorkshire, United Kingdom) and anti–RyR-PS2815 (1:5000) anti-
body generously provided by Dr A.R. Marks (Columbia University, New
York, NY).
Statistical Analysis
Preliminary descriptive analyses include frequencies for categorical
variables and meanSD for continuous variables. A conditional hier-
archical linear model was used (SAS/UNIX statistical software, SAS
Institute, Cary, NC; proc mixed) to compare continuous variables
between groups to take into account the multiple observations per
animal. The group was a fixed effect, and animals were a random effect
nested in the group; in the case of repeated measurements on cells, we
add a random effect for cell in animal.
Data are presented as meanSEM and were compared with
Student’s t test (for 2 groups) or ANOVA (for 2 groups, followed
by a post hoc pairwise Tukey’s honestly significant difference test).
Significance was defined at P0.05.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Aldosterone Pathway Increases Occurrence
of DADs
During AP recordings, at 0.1-Hz cycle length in ventricular
myocytes isolated from transgenic mice expressing hMR in the
heart (hMR mice; Figure 1A), we observed oscillations in
membrane potential after completion of the driven AP (Figure
1A, middle). Eventually, the DAD was large enough to reach
the threshold to trigger spontaneous AP (Figure 1A, right). The
occurrence of DADs was greatly enhanced by activation of the
aldosterone pathway (Figure 1B). Ex vivo, after 48 hours’
exposure of isolated rat ventricular myocytes to aldosterone 100
nmol/L, the occurrence of DADs increased compared with
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control myocytes kept 48 hours in the absence of aldosterone.
Likewise, in vivo, increases of DAD occurrence appeared after
3-week minipump infusion of aldosterone in WT mice or in
hMR mice compared with untreated WT littermates.
Modulation of Ca2 Sparks by
Aldosterone Pathway
DADs are commonly initiated by nonelectrically driven, spon-
taneous Ca2 release from the SR via the RyRs.8 We thus
examined the properties of RyRs in situ by visualizing sponta-
neous Ca2 sparks, which reflect brief and local Ca2 release
events that occur when RyRs open.18,19 Figure 2A shows
line-scan images of cells isolated from WT, aldosterone-treated,
and hMR mice. Either elevated circulating aldosterone or car-
diac hMR expression resulted in an 1.6-fold increase of Ca2
spark frequency (supplemental Table II; Figure 2B). No differ-
ences in mean values for Ca2 spark amplitude (Figure 2C) or
rise time (Figure 2D) were seen among the 3 groups. As seen in
Figure 2A, in addition to classic Ca2 sparks characterized by a
brief, localized increase in the fluorescence signal (a half-time of
decay of30 ms and a diameter of2 m),18 we also observed
the appearance of widened (4 m) and long-lasting Ca2
Figure 1. Activation of aldosterone pathway
increases occurrence of DADs. A, Representative
APs recorded from the same hMR cardiomyocyte,
elicited at 0.1 Hz, showing the appearance of
spontaneous depolarization (middle; DAD indicated
by arrow) and triggering spontaneous AP (right). B,
Bar graph plots number of cells presenting at least
1 DAD in rat ventricular myocytes incubated 48
hours with or without aldosterone 100 nmol/L and
in ventricular myocytes isolated from WT, aldoste-
rone-treated WT, and hMR littermate mice. n Indi-
cates total cell number. *P0.05. Aldo indicates
aldosterone; cont, control.
Figure 2. Change of spatiotemporal properties of Ca2 sparks induced by mineralocorticoid in vivo. A, Sample line-scan fluorescence
images record from cells isolated from WT (top), aldosterone-treated (WTAldo; middle), and hMR (bottom) mice. B through D, Com-
parison of frequency of occurrence, amplitude (F/F0), and rise time of Ca2 sparks at rest in myocytes from WT (open bars), WTAldo,
(light blue bars), and hMR (blue bars) mice. In B, n is the cell number, whereas in C and D, it is the number of Ca2 sparks. *P0.05.
Probability density function (PDf) of Ca2 spark widths (E; FWHM) and durations (F; FDHM) at half-maximal amplitude in WT, WTAldo,
and hMR mice. Curves represent mixed gaussian functions fitted to the histograms. In F, analyses were conducted on log(FDHM), and
corresponding results are presented after back transformation.
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release events (80 ms). A mixed-effects model revealed
increases of both averaged Ca2 spark full widths and full
durations at half-maximal amplitude in aldosterone-treated and
hMR mice (supplemental Table II), which might reflect differ-
ences in population proportions. The distributions of full width
and full duration at half maximum were empirically fitted to
bimodal gaussian functions (Figure 2E and 2F). The distribu-
tions of full width at half maximum showed a prominent mode
near 2.8 m and a second minor mode near 4.3 m, regardless
of the conditions; however, the proportion of events that showed
a larger width was greater in aldosterone-treated and hMR mice
than in WT mice (Table). Moreover, events that lasted 50 ms
were more frequent in aldosterone-treated and hMR mice than in
WT mice. Distributions of log(full duration at half maximum)
were fitted by 2 gaussian distributions with 2 distinct peaks at
32 and 87 ms, but the frequencies of long-lasting signals were
greater in aldosterone-treated and hMR mice than in WT
mice (Table). No correlation between Ca2 spark spatio-
temporal characteristics was observed. This is consistent
with the occurrence of 3 different populations of Ca2
sparks, the redistribution of which to long-lasting and more
widespread populations was increased by activation of the
cardiac aldosterone pathway.
Although the effects of aldosterone in vivo are presumably
due to its direct cardiomyocyte effect, aldosterone might cause
release of second messengers from noncardiac cells that can
affect Ca2 sparks. To exclude this possibility, we examined the
properties of spontaneous Ca2 sparks of isolated rat ventricular
Figure 3. Ex vivo aldosterone exposure promotes the occurrence of widespread and long-lasting Ca2 sparks. A through C, Representative
spark images and spatiotemporal profiles from a 48-hour aldosterone-treated cell showing that spontaneous Ca2 sparks can be short (A),
large (B), or long (C). The distance along the cell is represented vertically, and the time is represented horizontally. D and E, Probability den-
sity function (PDf) of full width (FWHM) and full duration (FDHM) at half-maximal amplitude after 48 hours’ incubation under conditions of
control (cont; red open bars) and 100-nmol/L aldosterone without (Aldo; blue bars) and with (AldoRU; blue open bars) 10-mol/L RU28318.
Histograms were fitted by the sum of 2 gaussian distributions. F through H, Bar graphs of meanSEM values for Ca2 spark frequency (F),
amplitude (F/F0; G), and rise time (H). In F, n is the cell number, whereas in G and H, it is the number of Ca2 sparks. **P0.005.
Table. Mean (), SD (), Proportion (p, in %), and Coefficient of Determination (r2) of Gaussian Fits to Ca2 Spark Parameters
FWHM, m FDHM, ms
1 1 p1 2 2 p2 r2 1 1 p1 2 2 p2 r2
Aldo in vivo
WT 2.79 0.91 93.5 4.32 0.60 6.5 0.98 30.9 5.6 96.0 85.2 23.9 4.0 0.98
WTAldo 2.80 0.84 83.8 4.30 1.20 16.2 0.99 32.4 5.9 91.0 87.6 30.2 9.0 0.99
hMR 2.78 0.71 70.2 4.33 1.15 28.8 0.99 33.4 5.9 81.6 89.4 27.9 18.4 0.99
Aldo ex vivo
Control 2.61 0.89 94.5 4.85 0.71 5.5 0.99 33.7 6.3 94.0 103.0 41.1 6.0 0.99
Aldo 2.62 0.91 72.0 4.60 1.25 28.0 0.99 33.5 6.3 81.7 106.0 50.3 18.3 0.99
AldoRU 2.54 0.78 95.8 4.53 0.70 4.2 0.99 33.7 5.7 95.7 105.3 35.2 4.3 0.99
Aldo indicates aldosterone; FWHM and FDHM, full width and duration at half-maximal amplitude; and AldoRU, aldosterone plus RU28318 (10 mol/L).
2182 Circulation April 28, 2009
 at Cardiff University on February 19, 2014http://circ.ahajournals.org/Downloaded from 
myocytes kept 48 hours with or without aldosterone 100 nmol/L.
Three different populations of Ca2 sparks were observed
(Figure 3): The normal Ca2 sparks were narrow and brief
(Figure 3A); the second population was substantially wider in
space but only slightly longer in duration (Figure 3B); and the
third population had the same width as the normal population but
was much longer in duration (Figure 3C). Analysis of the
distributions of full width at half maximum (Figure 3D) and full
duration at half maximum (Figure 3E) showed that ex vivo
aldosterone exposure increased the occurrence of both wider and
longer populations (Table; supplemental Table II). In addition,
we observed a 1.9-fold increase in Ca2 spark frequency (sup-
plemental Table II; Figure 3F), whereas mean Ca2 spark
amplitude (Figure 3G) and rise time (Figure 3H) were not
affected. Coincubation with a specific MR antagonist,
RU28318,11–13 prevented aldosterone-induced changes in Ca2
spark properties (Figure 3).
Aldosterone Effects on Ca2 Sparks Might Arise
From Modulation of RyR Intrinsic Properties
The open probability of RyRs is influenced by the amount of
Ca2 stored in the SR.20 A potential increase of SR Ca2 load by
aldosterone could therefore underlie the observed effects on
Ca2 sparks. SR Ca2 load was estimated by rapid caffeine
application (10 mmol/L) in the same intact cells used for Ca2
sparks.11,21 No difference (P0.05) was observed in hMR
mice (peak ratio of fluorescence intensity [F/F0] 4.00.1,
n56) or aldosterone-treated mice (3.80.2, n43) com-
pared with WT mice (4.10.1, n29). In addition, no
difference in caffeine-evoked Ca2 transients was noted
after ex vivo aldosterone exposure (3.70.2 and 4.00.2
in control [n13] and aldosterone-treated [n13] myo-
cytes, respectively; P0.05). These results are consistent
with the absence of alteration in Ca2 spark amplitude and
suggest that aldosterone does not modulate RyR activity
(and hence, Ca2 sparks) by altering SR content.
Ca2 sparks result from the opening of clusters of RyRs; thus,
increased Ca2 spark frequency might result from increased RyR
expression. Immunoblot analysis of cell lysates showed similar
RyR amounts; after normalization against control, ratios of RyR
to actin levels were 10.3 (n8), 0.950.3 (n4), and
0.820.3 (n4) in WT, WT plus aldosterone, and hMR mice,
respectively (P0.05) and 10.2 (n8) and 0.940.2 (n4) in
rat ventricular myocytes kept 48 hours without and with aldo-
Figure 4. Single RyR channels reconstituted in lipid bilayers display 3 different kinetic behaviors: (A) Short, (B) burst, and (C) long openings. Each
panel shows representative examples of single-channel behaviors of RyR reconstituted from the same SR-enriched membrane fraction of rat ven-
tricular myocytes incubated 48 hours in the presence of aldosterone. Top, 2-minute and 500-ms section of the recording on an expanded time
scale of single-channel traces recorded at 25 mV with channel openings (o) in the upward direction; Bottom, current-voltage relationship of the cor-
responding incorporated RyR. D, Bar graph plots the percentage of the occurrence of modal behaviors of reconstituted RyR channels from SR frac-
tions of cells kept 48 hours with (Aldo, shaded bars, n15) and without aldosterone (cont, open bars, n11). **P0.005.
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Figure 5. Downregulation of FKBP12 and FKBP12.6 expression after activation of cardiac aldosterone pathway. A–C, Representative
immunoblots and quantification of (A) FKBP12/12.6 protein levels in cardiac cell lysates (normalized to the corresponding actin level
and to respective controls) and (B) FKBP12/12.6 and RyR content in SR-enriched membrane fractions (cumulative data presented are
derived from 4 different heart preparations, each immunoblotted 4 times, and are illustrated after normalization against the WT, non-
treated sample). C, Pooled data represent ratios of RyR-P2815 and RyR-P2809 to RyR from SR-enriched membrane fractions normalized
(Continued)
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sterone, respectively (P0.05). RyR expression of isolated rat
cardiomyocytes kept 48 hours with or without aldosterone,
examined by [3H]ryanodine binding to SR fractions, indicated
unchanged high-affinity binding site for ryanodine (Kd values in
nmol/L: 1.50.2 and 1.80.4 after 48 hours’ incubation with
[n6] and without aldosterone [n6], respectively; P0.05)
and similar expression levels of RyR after aldosterone exposure
(maximal receptor density 0.240.04 and 0.290.03 pmol/mg
protein, respectively; P0.05).
These results show that activation of the aldosterone pathway
in cardiac myocytes altered Ca2 spark properties without
modifying SR Ca2 content or RyR expression. Therefore,
aldosterone modulation of Ca2 sparks might arise from changes
in the intrinsic activity of the RyR complex. As an index, we
fused SR fractions from control and aldosterone-treated rat
cardiomyocytes into planar lipid bilayers to record single-
channel activity of RyR. In addition to classic bimodal gating,20
characterized by sequences of flickering openings with low
(Figure 4A) and high (Figure 4B) open probability, clearly
distinct, long, relatively stable openings with similar unitary
current amplitude were observed (Figure 4C). Measurements
from holding potentials from 35 to 35 mV showed that
current-voltage relationships had similar conductances of 639,
632, and 640 pS (Figures 4A, 4B, and 4C, respectively). These
results suggest that all recorded channel activity corresponded to
RyRs; however, although the burst and long-lasting modes were
observed in channels with and without aldosterone treatment,
these modes occurred more frequently after aldosterone expo-
sure (Figure 4D).
FKBP12/12.6 Downregulation by
Mineralocorticoid Pathway
Taken together, the present results indicate that aldosterone
through MR increases the likelihood that RyRs will open
abnormally during diastole, which might reflect changes in
intrinsic properties of the RyR. Activity of RyRs is tightly
regulated by several accessory proteins that form a macromo-
lecular signaling complex with RyR.15,16 Among these ancillary
proteins, FKBP12 and FKBP12.6 have been involved in the
incidence of subsets of cardiac Ca2 sparks with longer duration
and wider spatial spread, along with increased frequency.21–23
Therefore, we assessed the expression of FKBP12/12.6 protein
levels. Compared with the respective controls, immunoblot
analysis of cell lysates showed decreases in the amount of
FKBP12/12.6 relative to actin levels after in vivo or ex vivo
aldosterone exposure and in hMR mice (Figure 5A). The
RyR-FKBP12/12.6 association was assessed indirectly by mea-
surement of the ratio of FKBP12/12.6 to RyR detected in the SR
fractions.24–26 Immunoblot analysis indicated that the relative
amount of FKBP12/12.6 to RyR was decreased in the hearts of
hMR mice or WT mice treated with aldosterone compared with
control WT (Figure 5B). Because RyR phosphorylation could
influence the FKBP12/12.6-RyR association,15,16 we examined
RyR phosphorylation status after activation of the mineralocor-
ticoid pathway. RyR contains multiple phosphorylation sites,
including RyR-Ser2815 (phosphorylated by CaMKII)27 and
RyR-Ser2809 (phosphorylated by both CaMKII and PKA).28
Using 2 different phosphospecific antibodies (RyR-PS2815 and
RyR-PS2809) on SR fractions, we observed no difference in the
ratio of phosphorylated RyR to total RyR among groups (Figure
5C). To distinguish FKBP12 versus FKBP12.6 expression,
real-time quantitative polymerase chain reaction was used to
assess mRNA levels with specific primers. At the mRNA level,
decreased expression of both FKBP12 and FKBP12.6 was
observed in the 3 models studied compared with respective
controls (Figure 5D), whereas mRNA levels of RyR were not
altered (data not shown).
Discussion
Long-term aldosterone exposure ex vivo or in vivo, or cardiac
hMR expression in transgenic mice, increases the occurrence
of DADs, in line with abnormal diastolic openings of RyR,
which are associated with downregulation of FKBP12 and
FKBP12.6. Although the link might be circumstantial, several
lines of evidence suggest that overstimulation of the cardiac
mineralocorticoid pathway may be a major upstream factor
for aberrant Ca2 release during diastole and may contribute
to cardiac arrhythmia in HF.
Numerous experimental and clinical studies indicate that
the aldosterone pathway participates in cardiac alterations
associated with hypertension, HF, diabetes mellitus, and other
pathologies.1,3–6,12,14 Notably, inappropriate activation of car-
diac MR is a likely participant in the development of poor
outcomes for patients with HF, especially those associated
with cardiac arrhythmia.5,6 Interestingly, hMR mice showed
high mortality and an increased occurrence of arrhythmia.14
One of the possible cellular mechanisms for those arrhyth-
mias is triggered activity caused by EADs and DADs, both
of which are commonly associated with intracellular Ca2
mishandling. We previously reported that along with AP
lengthening, EADs occur in hMR mice.14 The incidence of
EADs was 1%, 11%, and 14% in ventricular myocytes
isolated from WT, aldosterone-treated, and hMR littermate
mice, respectively. In addition, we observed that 10% of
rat ventricular myocytes incubated for 48 hours with
aldosterone displayed EADs, whereas none were observed
in control. Here, we found that the incidence of DAD was
approximately 2-fold higher, thus constituting a substantial
mechanism for aldosterone pathway–induced arrhythmias.
Although many Ca2-handling proteins are involved in
DAD-related arrhythmias, abnormal opening of the RyR
during diastole is an essential component.7,8 We show here
that the aldosterone pathway increased the occurrence and
changed the spatiotemporal properties of spontaneous Ca2
sparks. Similar alterations were found either ex vivo by
incubation of adult cardiac myocytes with aldosterone or in
Figure 5 (Continued). to respective controls from WT (open bars), aldosterone-treated WT (WTAldo, hatched bar), and hMR (solid
bars) mice and in rat ventricular myocytes incubated 48 hours with (Aldo, solid bar) or without (cont, open bar) aldosterone 100
nmol/L. D, Real-time reverse-transcription polymerase chain reaction analysis of cardiac tissue content of FKBP12 and FKBP12.6.
2-Microglobulin, GAPDH, HPRT, and UBC were used as reference genes, and relative mRNA levels were normalized to the geometric
average of relative quantities for reference genes. *P0.05.
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vivo in mouse hearts, either after chronic delivery of aldo-
sterone or after hMR expression. These consistent findings
suggest that direct activation of cardiac MR by aldosterone
modifies the Ca2 spark phenotype, independent of other
compensatory changes in vivo. Indeed, the ex vivo effects of
aldosterone are prevented by a specific MR antagonist. In
addition, hMR mice have increased aldosterone receptor activ-
ity, presumably due to physiological aldosterone levels, as
assessed by prevention of phenotype effects with MR antago-
nist.14 Moreover, MR antagonists also prevent other aldosterone-
induced cardiac effects.10,11,13
Although we cannot exclude that the effects might be second-
ary to other modulations in myocyte Ca2 handling, several lines
of evidence suggest that activation of MR by aldosterone
directly affects RyR activity. The increase in Ca2 spark fre-
quency is not due to an increase in SR Ca2 load but rather might
reflect a modulation of the intrinsic properties of the RyR
complex. In addition to the increase in Ca2 spark frequency, we
observed a redistribution of Ca2 sparks to long-lasting and
broader populations. These “abnormal” Ca2 sparks were also
seen in control conditions but at a much lower frequency. Others
have also found Ca2 sparks that are longer or wider than the
classic Ca2 sparks in control conditions.18,21,29–31 The incidence
of wide (2 m) and long (60 to 80 ms) Ca2 sparks is
increased in left ventricular hypertrophy in the dog without
alteration in Ca2 spark amplitude.32 Here, aldosterone exposure
or cardiac hMR expression increased the proportions of long and
wide Ca2 sparks from a range of 4% to 6% to a range of 9% to
19% and from a range of 4% to 6% to a range of 16% to 30%,
respectively, which constitutes a substantial effect. This indi-
cates that aldosterone does not induce a new kind of Ca2 spark
but modifies the activity of functional release units.
Along with this alteration, we observed a significant downregu-
lation of FKBP12 and FKBP12.6 expression without variation in
the density of RyRs. Even if other alterations contributed to the
observed modifications of Ca2 spark characteristics, no other
RyR-associated proteins have been shown to induce similar mod-
ulations to FKBP. FKBP12/12.6 binding to RyRs modulates the
Ca2-flux properties of the channel complex; in particular, it
regulates RyR open probability and stability at rest20,33,34 (but see
also Xiao et al35). FKBP12.6 removal by pharmacological ap-
proaches22,36,37 or in transgenic animal models,23 and conversely,
adenoviral short-term FKBP12.6 overexpression,21,38 modulated
Ca2 spark frequency and the occurrence of longer and wider Ca2
sparks in a manner similar to that observed here. We showed that
activation of the cardiac aldosterone pathway produced a decreased
expression of FKBPs. In addition, we assessed the RyR-FKBP12/
12.6 association in hMR transgenic and WT mice treated with
aldosterone. The present results suggest that in mouse hearts,
activation of the aldosterone pathway results in substantially re-
duced RyR-FKBP12/12.6 interaction, which could be the cause of
the observed RyR-mediated Ca2 leak. These effects are not
associated with alteration of RyR phosphorylation status but might
reflect a genomic regulation of FKBP12/12.6 by the cardiac
aldosterone pathway, as evidenced by the decrease in mRNA levels
of FKBP12 and FKBP12.6. Partial loss of FKBP12.6 from RyR in
HF has been shown to cause diastolic Ca2 leak, which may result
in a greater tendency for DAD to occur and consequent triggered
arrhythmias.15,16,23,39–45 In addition, myocardial FKBP12.6 overex-
pression prevents triggered arrhythmias in normal hearts, probably
by reducing diastolic SR Ca2 leakage.46 Beyond the controversial
hypothesis that excess RyR activity due to hyperphosphorylation
reduces RyR affinity for FKBP12.6,47 most of the studies showed a
reduction of FKBP protein level in HF.23,39–45 Thus, we suggest that
activation of the aldosterone pathway might be an essential step in
the cascade of molecular events leading to FKBP deficiency that
causes RyR Ca2 leakage and triggers malignant cardiac arrhyth-
mias in HF. Taken together, the present findings may explain in part
why the use of MR antagonists in addition to optimal medical
therapy is associated with improved survival and fewer sudden
cardiac deaths in patients.
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CLINICAL PERSPECTIVE
Defective calcium handling is a key contributor to the pathophysiology of heart failure, not only in the weakening of the heart’s
ability to pump blood but also in the erratic heart beats that cause sudden death. Research conducted to understand the molecular
mechanisms underlying those fatal arrhythmias has focused mainly on downstream mechanisms (the defective calcium-handling
processes) rather than the causes. The present study highlights the role of the cardiac aldosterone pathway as an upstream primary
molecular event that leads to defective calcium handling. Combining ex vivo and in vivo (transgenic mice) approaches and using
state-of-the-art Ca2 imaging, electrophysiology, and biochemistry methods, we provide the first evidence that downregulation
of FK506 binding proteins (also known as calstabins) through the aldosterone pathway causes defectiveness of ryanodine
receptor activity, which has been associated with the common pathogenic mechanism of sudden cardiac death and heart failure.
In addition, these findings underline the potential of mineralocorticoid receptor antagonists as antiarrhythmic therapy.
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SUPPLEMENTAL METHODS 
FK506 binding protein level in cell lysates. 
Cell lysate protein (75 µg) was fractionated on 20 % SDS-PAGE gels, transferred onto 
nitrocellulose membranes (1 h at 100 V, 0.45 µm Hybond ECL, GE Healthcare Bio-Sciences 
Corp, NJ, USA) and probed with anti-FKBP12/12.6 serum (Santa Cruz Biotechnology) 
diluted 1:200 in PBST buffer (in mmol/L: KH2PO4 3, Na2HPO4 10, NaCl 150, 0.1% Tween 
20, pH 7.2-7.4) with 1 % bovine serum albumin (BSA). Membranes were blocked overnight 
with 3 % BSA in PBST buffer before primary antibody addition. Membranes were incubated 
2 hour with secondary peroxidase-conjugate goat antiserum (diluted 1:15,000 in PBST, 
Sigma). Signals were developed by chemiluminiscence (Supersignal West Pico 
Chemiluminescent substrate, Pierce Biotechnology). The relative amount of protein on the 
blots was determined by densitometry using KodakID Software (v. 3.635, Molecular Imaging 
Systems). Actin signals were detected in the same blots with anti-actin serum (Sigma) and 
used as loading controls. 
RyR-FKBP12/12.6 association on SR fractions. 
SR fractions (50 µg) were resuspended in SDS-PAGE loading buffer (60 mmol/L Tris, 
2% SDS, 10% glycerol, 5mmol/L EDTA, 2% β-mercaptoethanol, 0.01% bromophenol blue, 
pH 6.8), heated at 85°C for 5min, and proteins were separated in a 4% SDS-PAGE gel 
strengthened with 0.5% agarose (for RyR analysis), or a 15% SDS-PAGE gel (for FKBP 
analysis). Proteins from 4% gels were electrophoretically transferred to a polyvinylidene 
difluoride membrane (Immobilon-P, Millipore) using a semi-dry transfer system (Trans-Blot 
SD, Bio-Rad) in transfer buffer (48mmol/L Tris, 39mmol/L glycine, 0.0375% SDS) at 22V 
for 4 hours. Proteins from 15% gels were transferred to PVDF membrane using a mini-wet 
blot transfer system (Bio-Rad) in buffer (26mmol/L Tris, 192mmol/L glycine, 20% methanol) 
at 200 mA for 1 hour. Primary antibodies were applied overnight at 4°C: FKBP12/12.6 
antibody at 1:200 dilution (Affinity BioReagents), RyR antibody at 1:1000 dilution (rabbit 
polyclonal antibody raised to RyR residues 4454-4474). Immunoreactive protein bands were 
visualized by enhanced chemiluminescence detection (ECL, GE Healthcare). Densitometric 
analysis was performed using a GS-700 scanner (Bio-Rad) and Quantity One software (Bio-
Rad). 
RyR phosphorylation. 
75 µg of protein were fractionated on 7.5 % SDS-PAGE gels, transferred onto PVDF 
membranes (2 h at 100 V, 0.45 µm Amersham). Then membranes were probed successively 
(after successive membrane stripping in 1mol/L Glycine solution [pH 7.2]) with anti-RyR 
(C3–33, 1:3000 diluted in PBST solution, Affinity BioReagents), anti–RyR-PS2809 (1:5000, 
Badrilla) and anti–RyR-PS2815 (1:5000) antibodies generously provided by Dr A.R. Marks 
(Columbia University, New York) diluted in TBST solution (in mmol/L Tris-HCl 50, NaCl 
150, 0.1% Tween 20, pH 7.4). Antibodies were revealed with secondary peroxidase-conjugate 
mouse or rabbit antiserum (1:15,000, Calbiochem). 
Ca2+ sparks analysis. 
Ca2+ sparks were recorded in intact myocytes loaded with fluorescent Ca2+ dye (Fluo-3 AM) 
Spontaneous Ca2+ sparks were obtained in quiescent cells. SR Ca2+ load was estimated by 
rapid caffeine (10 mmol/L) application. Images were obtained with a confocal microscopy 
(Meta Zeiss LSM 510, objective w.i. 63x, n.a. 1.2) by scanning the cell with an Argon laser 
every 1.54 ms; fluorescence was excited at 488 nm and emissions were collected at >505 nm. 
Image analyses were performed by homemade routines using IDL software (Research System 
Inc.). Images were corrected for the background fluorescence. The fluorescence values (F) 
were normalized by the basal fluorescence (F0) in order to obtain the fluorescence ratio (F/F0). 
 
The probability density functions ( ) ( )∆⋅= N total
aNaPDf , where N(a) is the histogram 
distribution of Ca2+ spark parameter a, Ntotal is the total number of Ca2+ sparks and ∆ is the 
binwidth, were modelled as a mixture of Gauss distributions according to:  
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where Pi is the proportion, µi the mean and σi the standard deviation of individual 
distribution. 
Goodness of fits were always examined by χ2 test (Σ (observed-expected)2/expected) and in 
all the cases >0.05, indication of the absence of major discrepancy between distributions and 
fits. 
For Ca2+ spark duration, analysis was conducted on log-transformed FDHM and the results 
are presented after back transformation, using the delta method (σI*10mean2)1/2 for conversion 
of σi. 
 
 
SUPPLEMENTAL TABLES 
Table S1. Primers used in real-time RT-PCR assays 
 
Gene Oligonucleotide sequence 
 Mice Rat 
FKBP12 
 
F-5’-ACTAGGCAAGCAGGAGGTGA-3’ 
R-5’-CTCCATAGGCATAGTCTGAGGAGAT-3’ 
F-5’-ACTAGGCAAGCAGGAGGTGA-3’ 
R-5’- CATAGGCATAGTCTGGGGAGAT-3’ 
FKBP12.6 
 
F-5’-AGAAGGCACTGCCCAGATGA-3’ 
R-5’-AAAGATGAGGGTGGCATTGG-3’ 
F-5’-AGAAGGCGCTGCCCAGATGA-3’ 
R-5’-AAAGATGAGGGTGGCATTGG-3’ 
RyR 
 
F-5’-CTTCGATGTTGGCCTTCAAGAG-3’ 
R-5’-CCAACACGCACTTTTTCTCCTT-3’ 
F-5’-GATGTTGGCCTTCAAGAGGATACCACA-3’ 
R-5’-CCAACCCGCACCTTTTCTCCTT-3’ 
β2-µG F-5’-TTCTATATCCTGGCTCACACTGAA-3’ 
R-5’-CACATGTCTCGATCCCAGTAGA-3’ 
F-5’-TTCTACATCCTGGCTCACACTGAA-3’ 
R-5’-ACATGTCTCGGTCCCAGGTGA-3’ 
GAPDH 
 
F-5’-AATGGTGAAGGTCGGTGTG-3’ 
R-5’-GAAGATGGTGATGGGCTTCC-3’ 
F-5’-TGATTCTACCCACGGCAAGTT-3’ 
R-5’-TGATGGGTTTCCCATTGATGA-3’ 
HPRT 
 
F-5’-CTCAACTTTAACTGGAAAGAATGTC-3’ 
R-5’-TCCTTTTCACCAGCAAGCT-3’ 
F-5’-CTCAACTTTAACTGGAAAGAATGTC-3’ 
R- 5’-TCCTTTTCACCAGCAAGCT-3’ 
UBC 
 
F-5’-AGCCCAGTGTTACCACCAAG-3’ 
R-5’-ACCCAAGAACAAGCACAAGG-3’ 
F-5’-AGCCCAGTGTTAACACCAAG-3’ 
R-5’-ACCCAAGAACAAGCACAAGG-3 
 
F and R, foward and reverse primers, respectively. Reference genes: β2-µG, β2- 
microglobulin, GAPDH, Glyceraldehyde 3-phosphate dehydrogenase, HPRT, Hypoxanthine-
guanine phosphoribosyltransferase, UBC, ubiquitin C. 
 
Table S2. Parameter estimates from mixed-effect models with random effects for 
animals and cells. 
 
 Ca2+ spark frequency 
(s-1.100µm-1) 
 Least Squares 
Mean 
95% confidence 
interval 
P-value vs. respective control
Aldo in vivo 
WT 
WT+Aldo 
hMR 
 
1.03 
1.82 
1.79 
 
0.86 to 1.23 
1.51 to 2.21 
1.49 to 2.14 
 
 
0.023 
0.023 
Global Type 3 test P=0.0347 
Aldo ex vivo 
control 
Aldo 
Aldo+RU 
 
0.70 
1.50 
0.61 
 
0.55 to 0.89 
1.17 to 1.92 
0.46 to 0.80 
 
 
0.0052 
0.4880 
Global Type 3 test P=0.0056 
 Ca2+ spark full width at half maximal amplitude 
(µm) 
Aldo in vivo 
WT 
WT+Aldo 
hMR 
 
2.68 
2.79 
3.02 
 
2.60 to 2.77 
2.71 to 2.88 
2.93 to 3.10 
 
 
0.0346 
0.0119 
Global Type 3 test P=0.0253 
Aldo ex vivo 
control 
Aldo 
Aldo+RU 
 
2.55 
2.88 
2.53 
 
2.44 to 2.66 
2.77 to 2.99 
2.40 to 2.66 
 
 
0.0069 
0.8183 
Global Type 3 test P=0.0091 
 Ca2+ spark full duration at half maximal amplitude 
(ms) 
Aldo in vivo 
WT 
WT+Aldo 
hMR 
 
31.62 
33.25 
39.02 
 
28.48 to 35.11 
29.93 to 36.95 
35.20 to 43.24 
 
 
0.0553 
0.0337 
Global Type 3 test P=0.0655 
Aldo ex vivo 
control 
Aldo 
Aldo+RU 
 
37.12 
43.98 
34.20 
 
33.60 to 41.01 
40.03 to 48.31 
30.57 to 38.26 
 
 
0.0515 
0.3259 
Global Type 3 test P=0.0345  
 
